<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Smoldering multiple myeloma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Smoldering multiple myeloma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Smoldering multiple myeloma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">María-Victoria Mateos, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H55635602"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Smoldering multiple myeloma (SMM) is diagnosed in persons who meet the following criteria  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum monoclonal (M) protein ≥3 g/dL and/or 10 to 59 percent bone marrow clonal plasma cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absence of lytic lesions, anemia, hypercalcemia, and kidney impairment (end-organ damage) that can be attributed to the plasma cell proliferative disorder <strong>and</strong> the absence of biomarkers associated with near inevitable progression to end-organ damage (≥60 percent clonal plasma cells in the marrow; involved/uninvolved free light chain [FLC] ratio of ≥100 with involved FLC &gt;100 mg/dL; or more than one focal bone lesion on magnetic resonance imaging [MRI]).</p><p></p><p>SMM is distinguished from multiple myeloma (MM) based on the lack of myeloma-defining events; it is distinguished from monoclonal gammopathy of undetermined significance (MGUS) based on the size of the M protein and the percentage of plasma cells in the bone marrow  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef98065" href="/z/d/graphic/98065.html" rel="external">table 3</a>).</p><p>The clinical course and management of patients with SMM will be discussed here. The diagnosis of this and other plasma cell dyscrasias, the recognition of serum or urinary M proteins, and the management of symptomatic MM are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6652.html" rel="external">"Diagnosis of monoclonal gammopathy of undetermined significance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="headingAnchor" id="H55635609"><span class="h1">DEFINITIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoldering multiple myeloma</strong> – Smoldering multiple myeloma (SMM) is defined as a monoclonal (M) protein ≥3 g/dL and/or 10 to 59 percent bone marrow plasma cells but no end-organ damage (lytic lesions, anemia, kidney disease, or hypercalcemia) that can be attributed to the underlying plasma cell disorder or other myeloma-defining events, and no amyloidosis  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>].</p><p></p><p class="bulletIndent1">Thus, for the diagnosis of SMM, patients should <strong>not</strong> have any of the following myeloma-defining events:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>End-organ damage (lytic lesions, anemia, kidney disease, or hypercalcemia) that can be attributed to the underlying plasma cell disorder.</p><p class="bulletIndent2"><span class="glyph">•</span>≥60 percent clonal plasma cells in the bone marrow [<a href="#rid3">3,4</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>Involved/uninvolved free light chain (FLC) ratio ≥100 with involved FLC &gt;100 mg/dL [<a href="#rid5">5-7</a>].</p><p class="bulletIndent2"><span class="glyph">•</span>MRI with more than one focal lesion &gt;5 mm (involving bone or bone marrow) [<a href="#rid8">8-11</a>].</p><p></p><p class="bulletIndent1">Asymptomatic patients with one or more of the myeloma-defining events listed above are considered to have multiple myeloma (MM) rather than SMM because they have a risk of progression with complications of greater than 80 percent within two years [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiation from MGUS</strong> – SMM is differentiated from monoclonal gammopathy of undetermined significance (MGUS) based on the size of the M protein and the level of bone marrow involvement  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef98065" href="/z/d/graphic/98065.html" rel="external">table 3</a>). It is considered a separate premalignant entity because the risk of progression is much higher than with MGUS especially during the first five years (10 percent per year for the first five years versus 1 percent per year, respectively). As a result, patients with SMM need more frequent follow-up compared with patients with MGUS, at least during the first five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiation from MM</strong> – SMM is differentiated from MM based on either the presence of end-organ damage or on the presence of at least one of the three biomarkers described above that accurately identify a subset of patients who are at imminent risk of developing end-organ damage  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>). If there are doubts about the differentiation of MGUS/SMM from MM and whether to begin treatment, one should re-evaluate in two or three months. Importantly, to be considered a criterion for the diagnosis of MM, the end-organ damage must be due to the plasma cell disorder. Examples of comorbidities that may mimic end-organ damage include kidney impairment related to hypertension or diabetes and anemia due to iron or vitamin deficiency. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p></p><p class="bulletIndent1">The management of MM and indications for treatment are presented in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Verify the diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H2891527298"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>There are limited data regarding the epidemiology of smoldering multiple myeloma (SMM) since it is an asymptomatic condition without a routine screening program. </p><p>The best data come from the iStopMM population-based study from Iceland in which &gt;75,000 asymptomatic adults over age 40 were screened with serum protein electrophoresis and serum free light chain assay [<a href="#rid12">12</a>]. Bone marrow biopsy was used to evaluate those with monoclonal paraprotein detected. </p><p>The prevalence of SMM in this population was 0.5 percent overall (95% CI 0.49-0.57 percent). Rates were higher in males (0.7 percent, 95% CI 0.62-0.73 percent) than in females (0.4 percent, 95% CI 0.35-0.43 percent), and increased with age from &lt;0.25 percent in those under 50 years to &gt;1 percent in those over 80 years. </p><p>Among the 193 individuals with SMM, median age was 70 years (range 44 to 92 years), and 60 percent were male. The mean M protein concentration was 0.62 g/dL (range 0.01 to 3.5 g/dL) and 73 percent had 11 to 20 percent bone marrow plasma cell infiltration.</p><p class="headingAnchor" id="H55639046"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>The natural history of patients with smoldering multiple myeloma (SMM) is variable. Patients progress to symptomatic myeloma or AL amyloidosis at approximate rates of  (<a class="graphic graphic_table graphicRef67431" href="/z/d/graphic/67431.html" rel="external">table 4</a>) [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>10 percent per year for the first five years</p><p class="bulletIndent1"><span class="glyph">●</span>3 percent per year for the next five years</p><p class="bulletIndent1"><span class="glyph">●</span>1 to 2 percent per year for the following 10 years </p><p></p><p>As such, most patients with SMM will progress with a median time to progression of 4.8 years. A simple risk stratification schema can identify those patients who are more or less likely to progress over the next two years and can guide therapy  (<a class="graphic graphic_algorithm graphicRef126135" href="/z/d/graphic/126135.html" rel="external">algorithm 2</a>). (See <a class="local">'Risk stratification'</a> below.)</p><p class="headingAnchor" id="H55635621"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H483596406"><span class="h2">Risk stratification</span><span class="headingEndMark"> — </span>We risk stratify individuals with smoldering multiple myeloma (SMM) using the Mayo 2018/International Myeloma Working Group (IMWG) risk stratification system (also called the 20/2/20 criteria), which takes into consideration the following three risk factors for progression [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow plasma cells &gt;20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal (M) protein &gt;2 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Involved/uninvolved free light chain (FLC) ratio &gt;20</p><p></p><p>In one analysis of 417 patients with SMM diagnosed according to 2014 diagnostic criteria and followed without intervention, these risk factors were able to stratify patients into three risk groups with distinctly different patterns of progression [<a href="#rid1">1,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>High risk (two or three factors present) – Estimated median time to progression (TTP) 29 months; estimated risk of progression of 24 percent per year during the first two years, 11 percent per year for the next three years, and 3 percent per year for the next five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk (one factor present) – Estimated median TTP 68 months; estimated rate of progression of 15 percent per year during the first two years, 7 percent per year for the next three years, and 4 percent per year for the next five years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low risk (no factors present) – Estimated median TTP of 110 months; estimated rate of progression of 5 percent per year during the first 10 years.</p><p></p><p>The 20/2/20 criteria were validated in a retrospective analysis of 1151 patients with SMM [<a href="#rid15">15</a>]. The estimated progression rates at two years were 6, 18, and 44 percent among those with low-risk, intermediate-risk, and high-risk disease, respectively. </p><p>Additional risk factors for progression that have been identified in some, but not all, studies include  (<a class="graphic graphic_table graphicRef109720" href="/z/d/graphic/109720.html" rel="external">table 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Immunoglobulin A (IgA) isotype [<a href="#rid13">13</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Immunoparesis with reduction of two uninvolved immunoglobulin isotypes [<a href="#rid13">13,16,17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal plasma cell immunophenotype with immunoparesis (reduction of ≥1 uninvolved immunoglobulin isotypes) [<a href="#rid17">17,18</a>]. In contrast, an MGUS-like immunophenotype on flow cytometry may be associated with a lower risk of progression [<a href="#rid19">19</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Increased circulating plasma cells by immunofluorescence [<a href="#rid20">20</a>] or flow cytometry [<a href="#rid21">21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Detection of lesions on MRI of the spine and pelvis [<a href="#rid22">22</a>], evolving pattern of M-spike [<a href="#rid23">23,24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of Bence Jones proteinuria in IgG or IgA SMM [<a href="#rid25">25</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>PET/computed tomography (CT) with focal lesion with increased uptake without underlying osteolytic bone destruction [<a href="#rid26">26,27</a>].</p><p></p><p>While initial studies suggest genetic features may impact prognosis  (<a class="graphic graphic_table graphicRef109721" href="/z/d/graphic/109721.html" rel="external">table 6</a>), these results must be validated and compared with clinical features before they can be routinely applied to clinical practice.</p><p>In one study, TTP and overall survival (OS) were shorter in patients with t(4;14) when compared with those with t(11;14) [<a href="#rid28">28</a>]. A trend toward shorter TTP has also been seen in patients with deletion 17p, gain 1q21, and hyperdiploidy [<a href="#rid28">28,29</a>].</p><p>The impact of genetic changes on prognosis appears to be strongest in patients with a low tumor burden. In a prospective study of 179 patients with SMM, those with a high-risk gene expression profile signature had a higher rate of progression to symptomatic multiple myeloma (MM) at two years (51 versus 12 percent) [<a href="#rid30">30</a>]. </p><p class="headingAnchor" id="H3205426042"><span class="h2">Management of low- or intermediate-risk SMM</span><span class="headingEndMark"> — </span>Observation with deferral of treatment until disease progression is standard for patients with low-risk SMM  (<a class="graphic graphic_algorithm graphicRef126135" href="/z/d/graphic/126135.html" rel="external">algorithm 2</a>). For patients with intermediate-risk SMM, we also suggest close observation rather than treatment. A clearly increasing level of the M protein in the serum or urine suggests that therapy will be needed in the near future. </p><p>Some patients with low-risk or intermediate-risk SMM can remain stable without treatment over extended periods of time, and it is not clear that treatment with available therapies improves outcomes [<a href="#rid2">2,31-34</a>]. In randomized studies that compared melphalan-based therapy at diagnosis versus deferral of chemotherapy until progression, early treatment delayed progression, but did not improve OS, and was associated with an increase in acute leukemia [<a href="#rid32">32</a>]. In addition, a subgroup analysis of the randomized trial comparing single-agent <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> versus observation in SMM did not demonstrate a progression-free survival (PFS) or OS benefit in those with low-risk or intermediate-risk SMM [<a href="#rid35">35</a>]. (See <a class="local">'Management of high-risk SMM'</a> below.) </p><p class="headingAnchor" id="H55635627"><span class="h3">Monitoring for progression</span><span class="headingEndMark"> — </span>Our approach to monitoring individuals with low- or intermediate-risk SMM is similar to that suggested by the IMWG [<a href="#rid1">1,36,37</a>]. At the time of diagnosis, we perform the following to rule out end-organ damage and other findings that are diagnostic of MM:</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies should include a serum protein electrophoresis (SPEP), complete blood count (CBC), serum creatinine, serum calcium, urine protein electrophoresis (UPEP) with immunofixation, FLC ratio, and bone marrow biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cross-sectional imaging with either low-dose whole-body CT without contrast or whole-body combined fluorine-18-labeled fluorodeoxyglucose positron emission tomography/computed tomography (<sup>18</sup>F-FDG PET/CT), followed by a whole-body MRI or MRI of the spine and pelvis. Conventional skeletal surveys are no longer a preferred imaging modality. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Choice of modality'</a>.)</p><p></p><p>Two to three months after this testing, we again measure the SPEP, CBC, creatinine, calcium, FLC ratio, UPEP, and urine immunofixation. If the results of these tests are stable, the span of time between testing can be lengthened to every four to six months for one year, then to every 6 to 12 months. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Evaluation'</a>.)</p><p>Follow-up imaging studies must balance the potential cost and toxicity with the risk of progression [<a href="#rid37">37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SMM and no lesions on initial CT (or PET/CT) and MRI, we perform annual MRI to monitor for the development of asymptomatic bone lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SMM whose initial imaging demonstrated one focal lesion on MRI, we image every six months, alternating whole-body MRI and whole-body low-dose CT or PET/CT.</p><p></p><p>Other patients who may warrant imaging every six months include those with diffuse infiltration of the bone marrow on initial MRI and those with equivocal findings on initial imaging. In patients with otherwise asymptomatic myeloma, the identification of more than one focal bone lesion on MRI is diagnostic of MM and an indication for therapy. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p>The importance of monitoring M protein and hemoglobin levels was illustrated in a single-center retrospective study of 190 patients with SMM, which identified those with two to three of the following risk factors as having a high risk of progression within two years, thereby potentially meriting further work-up and/or therapy [<a href="#rid24">24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An evolving monoclonal protein level (eMP) defined as an increase in the M protein level of ≥25 percent within the first 12 months (minimum increase ≥0.5 g/dL) and/or a ≥10 percent increase within the first six months of diagnosis in patients with a baseline M protein ≥3 g/dL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An evolving change in hemoglobin (eHb) defined as decrease in hemoglobin concentration by ≥0.5 g/dL within 12 months of diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow plasma cells ≥20 percent.</p><p></p><p>The median time to progression was 12, 5, 2, and 1 years among patients with zero, one, two, and three risk factors respectively. The two-year progression risk was 82 percent in individuals who demonstrated both eMP and eHb, and 91 percent in those with all three risk factors. (See <a class="local">'Management of high-risk SMM'</a> below.)</p><p class="headingAnchor" id="H55638741"><span class="h3">Monitoring for complications</span><span class="headingEndMark"> — </span>Patients with SMM are at increased risk for complications, including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoporosis</strong> – Patients with SMM should be evaluated for osteoporosis with a dual energy x-ray absorptiometry (DEXA) scan and have their vitamin D and calcium intake optimized. If osteoporosis is present, treatment with bisphosphonates may be considered at the same dosing and schedule used for osteoporosis in patients without SMM. Analogs of PTH (eg, <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>) and PTH-related protein (eg, <a class="drug drug_general" data-topicid="112992" href="/z/d/drug information/112992.html" rel="external">abaloparatide</a>) are generally avoided due to their tendency to exacerbate hypercalcemia. (See  <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors", section on 'Use in smoldering MM, MGUS, or solitary plasmacytoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thromboembolism</strong> – There is an increased incidence of venous thromboembolic disease (VTE) and arterial thrombosis in patients with plasma cell dyscrasias, including SMM [<a href="#rid38">38-40</a>]. While the mechanisms involving this increased incidence are unclear, a hypercoagulable state secondary to an ongoing clonal plasma cell activity has been suggested [<a href="#rid40">40,41</a>]. Despite this, SMM itself is not an indication for VTE prophylaxis or specific avoidance of medications that increase risk for VTE. (See  <a class="medical medical_review" href="/z/d/html/1332.html" rel="external">"Multiple myeloma: Prevention of venous thromboembolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections</strong> – Patients with plasma cell dyscrasias have an increased risk of developing bacterial and viral infections over that seen in the general population. There are limited data regarding the magnitude of this risk, but it likely falls between that of monoclonal gammopathy of undetermined significance (MGUS; approximately twofold increased risk [<a href="#rid42">42,43</a>]) and that of symptomatic MM (approximately sevenfold increased risk [<a href="#rid44">44</a>]). For most patients, we follow standard age-based vaccine recommendations that do not differ from the general population. For patients who begin myeloma-directed therapy, we follow an approach similar to that used for patients treated for MM. (See  <a class="medical medical_review" href="/z/d/html/13947.html" rel="external">"Infections in patients with multiple myeloma"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second cancers</strong> – Persons with MGUS, SMM, and MM also have a higher incidence of developing second cancers [<a href="#rid45">45</a>]. We recommend that patients with SMM be encouraged to participate in age-appropriate cancer screening programs. No additional cancer screening has been recommended for this population. (See  <a class="medical medical_review" href="/z/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance", section on 'Second malignancies'</a>.) </p><p></p><p class="headingAnchor" id="H28402942"><span class="h2">Management of high-risk SMM</span><span class="headingEndMark"> — </span>For patients with high-risk SMM by the Mayo 2018/IMWG 20/2/20 criteria, we recommend treatment with single-agent <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> or lenalidomide plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> rather than observation, as this approach has been shown to prevent end-organ damage  (<a class="graphic graphic_algorithm graphicRef126135" href="/z/d/graphic/126135.html" rel="external">algorithm 2</a>). Clinical trials are evaluating other approaches such as single-agent <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a> and more intensive combination regimens [<a href="#rid46">46,47</a>]; such approaches should be reserved for clinical trials. Patients who want to delay therapy need close observation with evaluation for progression every three to four months, and treatment if there is evidence of progression or an evolving pattern (rising M protein or FLC level). Those with baseline abnormalities on MRI (diffuse infiltration, solitary focal lesion, or equivocal lesions) should have a repeat MRI in three to six months.</p><p>Lenalidomide-based therapy should mimic one of the protocols used in the randomized trials described below. Options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> 25 mg on the first 21 days of each 28-day cycle, continued as tolerated for up to two years [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> 25 mg on the first 21 days of each 28-day cycle plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 40 mg weekly [<a href="#rid18">18</a>]. After nine cycles, reduce the lenalidomide dose to 10 mg and discontinue dexamethasone. Continue as tolerated for up to two years. </p><p></p><p>Adjustments are needed for those with kidney dysfunction, and routine antithrombotic prophylaxis is warranted for all. <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> is myelosuppressive and we advise stem cell collection after four cycles in transplant-eligible patients. (See  <a class="medical medical_review" href="/z/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Immunomodulatory drugs'</a>.)</p><p>Two randomized trials have compared lenalidomide-based therapy versus observation in high-risk SMM [<a href="#rid18">18,35,48,49</a>]. The trials differed in selection criteria, the definition used for high-risk SMM, and in the treatment regimen. Both demonstrated an 80 to 90 percent risk reduction in end-organ damage. One demonstrated an improvement in OS [<a href="#rid18">18,48,49</a>].</p><p>A multicenter randomized trial compared single-agent <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> versus observation in 182 patients with SMM [<a href="#rid35">35</a>]. SMM diagnosis was made using 2014 IMWG criteria and required cross sectional imaging. All patients were risk stratified using the Mayo 2018/IMWG (20/2/20) criteria. Progression was defined as the development of symptomatic MM as evidenced by biochemical disease progression or related end-organ damage. After a median follow-up of 35 months, the following were noted:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> improved PFS in the entire study population (93 versus 76 percent at two years; HR 0.28, 95% CI 0.12-0.62). In the lenalidomide arm, there were fewer progression events due to end-organ damage, including fewer cases of kidney failure (0 versus 3 events) and bone lesions (3 versus 11 events). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On subgroup analysis, the PFS benefit was clear in patients with high-risk SMM (HR 0.09, 95% CI 0.02-0.44) but did not reach statistical significance in those with intermediate-risk SMM (HR 0.52, 95% CI 0.15-1.85).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longer follow-up is needed to evaluate OS. There were two deaths in the <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> arm and four deaths in the observation arm (HR for death 0.46, 95% CI 0.08-2.53).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most toxicities were managed with dose modifications. Approximately 20 percent of patients stopped <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> early due to toxicities.</p><p></p><p>Another multicenter randomized trial compared immediate treatment with <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (Rd) for nine cycles followed by single-agent lenalidomide to complete a total treatment duration of two years versus observation until progression in 119 patients with SMM at high risk of progression [<a href="#rid18">18,48,49</a>]. SMM diagnosis was made based on the absence of end-organ damage and did not incorporate modern biochemical diagnostic criteria or cross-sectional imaging. In this study, high-risk SMM was defined as:</p><p class="bulletIndent1"><span class="glyph">●</span>≥10 percent clonal bone marrow plasma cells plus presence of a monoclonal component (serum IgG ≥3 g/dL, IgA ≥2 g/dL, or Bence-Jones proteinuria &gt;1 g/24 hours); or</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One of the two criteria above plus aberrant plasma cell immunophenotype in &gt;95 percent of clonal plasma cells and immunoparesis (reduction in one or more uninvolved immunoglobulins by more than 25 percent compared with normal)</p><p></p><p>At a median follow-up of 12.5 years, immediate treatment with Rd resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>Improved PFS (median 9.5 years versus 2.1 years; HR 0.28; 95% CI 0.18-0.44). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved OS (median not reached versus 8.5 years; HR 0.57; 95% CI 0.34-0.95). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One treatment-related death (a respiratory infection). Severe (grade 3/4) toxicities included infection (6 percent), asthenia (6 percent), neutropenia (5 percent), rash (3 percent), and more second primary malignancies (6 versus 1).</p><p></p><p>Interpretation of this study can be limited by the method used to define high-risk SMM, which required flow cytometric assessment of plasma cell immunophenotype in approximately 50 percent of patients, although the classic Mayo Model was also used, and 45 percent of the patients met its criteria for the definition of high-risk. The median age of the control group was higher than the treatment group. </p><p class="headingAnchor" id="H759190336"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a>.)</p><p class="headingAnchor" id="H55638774"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_basics" href="/z/d/html/15531.html" rel="external">"Patient education: Multiple myeloma (The Basics)"</a>.)</p><p></p><p class="headingAnchor" id="H55635718"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and distinction from other entities</strong> – Smoldering multiple myeloma (SMM) is defined as a monoclonal (M) protein ≥3 g/dL and/or 10 to 59 percent bone marrow plasma cells but no end-organ damage (lytic lesions, anemia, renal disease, or hypercalcemia) that can be attributed to the underlying plasma cell disorder or other myeloma-defining events, and no amyloidosis  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>). Patients with SMM are distinguished from those with monoclonal gammopathy of undetermined significance (MGUS) by the size of the M protein and the level of bone marrow involvement, and from multiple myeloma (MM) by the absence of any myeloma-defining event  (<a class="graphic graphic_table graphicRef130091" href="/z/d/graphic/130091.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef98065" href="/z/d/graphic/98065.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Verify the diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history</strong> – The natural history of patients with SMM is variable. Patients with SMM will progress to symptomatic MM or AL amyloidosis at an approximate rate of 10 percent per year for the first five years, 3 percent per year for the next five years, and 1 to 2 percent per year for the following 10 years. As such, most patients with SMM will progress with a median time to progression of 4.8 years. (See <a class="local">'Clinical course'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification</strong> – We risk stratify individuals with SMM using the Mayo 2018/IMWG risk stratification system (also called the 20/2/20 criteria). Individuals with two or three of the following risk factors are considered to have high-risk SMM (see <a class="local">'Risk stratification'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow plasma cells &gt;20 percent</p><p class="bulletIndent2"><span class="glyph">•</span>M protein &gt;2 g/dL</p><p class="bulletIndent2"><span class="glyph">•</span>Involved/uninvolved free light chain (FLC) ratio &gt;20</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of low- and intermediate-risk SMM</strong> – Observation with deferral of treatment is standard for patients with low-risk SMM  (<a class="graphic graphic_algorithm graphicRef126135" href="/z/d/graphic/126135.html" rel="external">algorithm 2</a>). For patients with intermediate-risk SMM, we suggest observation rather than treatment (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Some patients with low-risk or intermediate-risk SMM can remain stable without treatment over extended periods of time, and it is not clear that treatment with available therapies improves outcomes. (See <a class="local">'Monitoring for progression'</a> above.)</p><p></p><p class="bulletIndent1">Prompt initiation of therapy is indicated in patients with MM. The following findings, if attributable to the underlying plasma cell disorder, are diagnostic of MM  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>): anemia, hypercalcemia, kidney impairment, lytic bone lesions, and extramedullary plasmacytoma. In addition, the following are diagnostic biomarkers of MM in the absence of symptoms: ≥60 percent clonal plasma cells in the marrow; involved/uninvolved FLC ratio ≥100; or more than one focal bone lesion on MRI. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Verify the diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of high-risk SMM</strong> – For patients with high-risk SMM, we recommend treatment with single-agent <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> or lenalidomide plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> rather than observation  (<a class="graphic graphic_algorithm graphicRef126135" href="/z/d/graphic/126135.html" rel="external">algorithm 2</a>) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In this population, early treatment prevents end-organ damage and may improve overall survival. More intensive regimens should be reserved for clinical trials. (See <a class="local">'Management of high-risk SMM'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538.</a></li><li><a class="nounderline abstract_t">Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302:1347.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol 2012; 9:494.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365:474.</a></li><li><a class="nounderline abstract_t">Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88:360.</a></li><li><a class="nounderline abstract_t">Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013; 27:941.</a></li><li><a class="nounderline abstract_t">Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111:785.</a></li><li><a class="nounderline abstract_t">Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28:1606.</a></li><li><a class="nounderline abstract_t">Kastritis E, Moulopoulos LA, Terpos E, et al. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia 2014; 28:2402.</a></li><li><a class="nounderline abstract_t">Merz M, Hielscher T, Wagner B, et al. Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma. Leukemia 2014; 28:1902.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33:657.</a></li><li><a class="nounderline abstract_t">Thorsteinsdóttir S, Gíslason GK, Aspelund T, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med 2023; 29:467.</a></li><li><a class="nounderline abstract_t">Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356:2582.</a></li><li><a class="nounderline abstract_t">Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018; 8:59.</a></li><li><a class="nounderline abstract_t">Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 2020; 10:102.</a></li><li><a class="nounderline abstract_t">Kyle RA, Larson DR, Therneau TM, et al. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol 2014; 1:e28.</a></li><li><a class="nounderline abstract_t">Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110:2586.</a></li><li><a class="nounderline abstract_t">Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013; 369:438.</a></li><li><a class="nounderline abstract_t">Burgos L, Tamariz-Amador LE, Puig N, et al. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. J Clin Oncol 2023; 41:3019.</a></li><li><a class="nounderline abstract_t">Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia 2013; 27:680.</a></li><li><a class="nounderline abstract_t">Termini R, Žihala D, Terpos E, et al. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma. Clin Cancer Res 2022; 28:4771.</a></li><li><a class="nounderline abstract_t">Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013; 122:4172.</a></li><li><a class="nounderline abstract_t">Fernández de Larrea C, Isola I, Pereira A, et al. Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 2018; 32:1427.</a></li><li><a class="nounderline abstract_t">Ravi P, Kumar S, Larsen JT, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016; 6:e454.</a></li><li><a class="nounderline abstract_t">González-Calle V, Dávila J, Escalante F, et al. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia 2016; 30:2026.</a></li><li><a class="nounderline abstract_t">Zamagni E, Nanni C, Gay F, et al. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 2016; 30:417.</a></li><li><a class="nounderline abstract_t">Siontis B, Kumar S, Dispenzieri A, et al. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J 2015; 5:e364.</a></li><li><a class="nounderline abstract_t">Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27:1738.</a></li><li><a class="nounderline abstract_t">Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013; 31:4325.</a></li><li><a class="nounderline abstract_t">Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014; 123:78.</a></li><li><a class="nounderline abstract_t">UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115:522.</a></li><li><a class="nounderline abstract_t">He Y, Wheatley K, Clark O, et al. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev 2003; :CD004023.</a></li><li><a class="nounderline abstract_t">Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden. Eur J Haematol 1993; 50:95.</a></li><li><a class="nounderline abstract_t">Grignani G, Gobbi PG, Formisano R, et al. A prognostic index for multiple myeloma. Br J Cancer 1996; 73:1101.</a></li><li><a class="nounderline abstract_t">Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2020; 38:1126.</a></li><li><a class="nounderline abstract_t">Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24:1121.</a></li><li><a class="nounderline abstract_t">Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol 2019; 20:e302.</a></li><li><a class="nounderline abstract_t">Srkalovic G, Cameron MG, Rybicki L, et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101:558.</a></li><li><a class="nounderline abstract_t">Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 2008; 112:3582.</a></li><li><a class="nounderline abstract_t">Kristinsson SY, Pfeiffer RM, Björkholm M, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010; 115:4991.</a></li><li><a class="nounderline abstract_t">Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. Clin Lymphoma Myeloma 2007; 7:462.</a></li><li><a class="nounderline abstract_t">Kristinsson SY, Björkholm M, Andersson TM, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica 2009; 94:1714.</a></li><li><a class="nounderline abstract_t">Gregersen H, Madsen KM, Sørensen HT, et al. The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance. Eur J Haematol 1998; 61:140.</a></li><li><a class="nounderline abstract_t">Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015; 100:107.</a></li><li><a class="nounderline abstract_t">Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012; 119:2731.</a></li><li><a class="nounderline abstract_t">Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 2020; 34:1840.</a></li><li><a class="nounderline abstract_t">Kazandjian D, Hill E, Dew A, et al. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 2021; 7:1678.</a></li><li><a class="nounderline abstract_t">Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol 2016; 17:1127.</a></li><li><a class="nounderline abstract_t">Mateos MV, Hernández MT, Salvador C, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. Eur J Cancer 2022; 174:243.</a></li></ol></div><div id="topicVersionRevision">Topic 95372 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25439696" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7374679" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850755" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Haematological cancer: Redefining myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812699" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis of smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23541011" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23183428" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17942755" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177023" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25079172" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24535407" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605835" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36747117" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of smoldering multiple myeloma based on nationwide screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582068" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29895887" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33067414" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25530988" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576818" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23902483" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36930848" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22902364" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36074126" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24144641" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Smoldering multiple myeloma requiring treatment: time for a new definition?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463830" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27471870" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133826" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26490489" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26495861" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515097" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145347" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24144643" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11736932" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Diagnosis and management of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535504" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Early versus deferred treatment for early stage multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8440364" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624271" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A prognostic index for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31652094" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410922" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31162104" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15274069" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559977" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299513" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875234" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19608666" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9714528" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The risk of bacteremia in patients with monoclonal gammopathy of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25344526" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22310913" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Second malignancies after multiple myeloma: from 1960s to 2010s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32024950" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34529025" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27402145" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36067617" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
